Slide 1: Managing Director's Report 12 Months to 31 July 2019
For personal use only Managing Director’s Report 12 Months to 31 July 2019 20 September 2019
Slide 2: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to adults, infants and children. 1
Slide 3: Full Year Performance Highlights
Full Year Performance Highlights For personal use only Total full year Revenue New products delivering $76.7m up 21.8% growth in new segments and countries on FY18 $63.0m driven by improved demand Inventory at $27.7m up $7.9m on FY18 full year Net Profit $10.1m up upon forward demand 33.1% on FY
Slide 4: Full Year 2019 Results
For personal use only Full Year 2019 Results AUD million 4E Reported 4E Reported 22% year on year revenue 31 Jul 2019 31 Jul 2018 growth Revenue $76.7 $62.9 High sales growth rates in EBITDA $14.0 $10.9 Asia, EU & USA, whilst Australia/NZ still key sales NPBT $14.0 $10.6 region Tax ($3.9) ($3.0)
Slide 5: Balance Sheet July 2019
Balance Sheet 31 July 2019 For personal use only AUD million Reported Reported Movement 31 Jul 2019 31 Jul 2018 Cash $8.3 $7.9 +$0.4m Net debt of $5.2m as compares to Trade Receivables $18.4 $15.3 +$3.1m EBITDA of $14.0m Inventories $27.7 $19.8 +$7.9m Trade receivables Total Current $55.4 $43.6
Slide 6: Sales by Geography & Product
Sales by Geography & Product For personal use only Sales across all key regions have grown during FY19 compared to FY18 Asia key growth area for IF for the Chinese market, whilst USA growth in non IF sector FY 2019 Geograph i c FY 2019 Americas 5% Product FY 2018 Europe FY 2018 8% Geographic Pro
Slide 7: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Focus on Infant Formula New New Product Market Development Development 6
Slide 8: Growth Platform: New products driving future growth
For personal use only Growth Platform New products driving future growth Clover’s new products have won new business in food fortification across different segments The highly concentrated DHA powder delivering a 60% oil loading is used across health bars, powders and gummies Clover has releas
Slide 9: Growth Platform: Infant formula maintains growth
Focus on For personal use only Infant Growth Platform Formula Infant formula maintains growth China adds 22 Bonded warehouses to facilitate CBEC (Cross Border Electronic Commerce) trade Awarding of SAMR licenses, to market and sell product in China’s retail channel, remains slow China has rele
Slide 10: Growth Platform: New markets development
For personal use only Growth Platform New markets development Clover has grown sales in USA, Europe, Asia and ANZ The USA has delivered sales growth across food, drink and nutraceutical applications Clover has sales staff across Europe, China, New Zealand and dedicated staff for SE Asia and Au
Slide 11: 1HFY20 Outlook & Priorities
1HFY20 Outlook & Priorities For personal use only Growth in European markets driven by the requirement to increase DHA levels in infant formula Build completion of spray drying facility in Hamilton, New Zealand Development of new products targeting sports nutrition, children’s and seniors’ hea
Slide 12: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s